Severe fibrosis in patients with recurrent hepatitis C after liver transplantation: A French experience on 250 patients over 15years (the Orfèvre study)

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 3, 2014, Pages 292-299

  Dumortier, JérÔme ^a   Salamé, Ephrem ^b   Roche, Bruno ^c   Hurtova, Monika ^d   Conti, Filomena ^e   Radenne, Sylvie ^f   Vanlemmens, Claire ^g   Pageaux, Georges Philippe ^h   Saliba, Faouzi ^c   Samuel, Didier ^c   Compagnon, Philippe ^d   Neau Cransac, Martine ⁱ   Calmus, Yvon ^e   Guillaud, Olivier ^a   Gugenheim, Jean ^j   Altieri, Mario ^k   Durand, François ^l   Hardwigsen, Jean ^m   Lorho, Richard ⁿ   Dharancy, Sébastien ^o   Leroy, Vincent ^p   Di Giambattista, Fabienne ^q   Duvoux, Christophe ^d   more..

^a EDOUARD HERRIOT HOSPITAL   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e Institut Cochin   (France)

^f CROIX ROUSSE HOSPITAL   (France)

^g UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^h HÔPITAL SAINT ELOI   (France)

ⁱ HÔPITAL PELLEGRIN   (France)

^j CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^k CHU CÔTE DE NACRE   (France)

^l BEAUJON HOSPITAL   (France)

^m HÔPITAL DE LA CONCEPTION   (France)

ⁿ PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^o LILLE UNIVERSITY HOSPITAL   (France)

^p HÔPITAL MICHALLON   (France)

^q NOVARTIS PHARMA K K   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; INTERFERON; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIVIRUS AGENT;

ACUTE GRAFT REJECTION; ADOLESCENT; AGED; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; COLD ISCHEMIA; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DONOR; FEMALE; HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MASS; OBSERVATIONAL STUDY; RECURRENT DISEASE; REINFECTION; RISK FACTOR; TREATMENT REFUSAL; TREATMENT RESPONSE; ADULT; AGE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DISEASE COURSE; DRUG RESISTANCE; FRANCE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; FRANCE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TISSUE DONORS;

EID: 84902553821     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.02.007     Document Type: Article

References (48)

1. Adam R., McMaster P., O'Grady J.G., Castaing D., Klempnauer J.L., Jamieson N., et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003, 9:1231-1243.
2. Merion R.M. Current status and future of liver transplantation. Semin Liver Dis 2010, 30:411-421.
3. Gane E.J. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008, 14(Suppl.2):S36-S44.
4. Feray C., Caccamo L., Alexander G.J., Ducot B., Gugenheim J., Casanovas T., et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999, 117:619-625.
5. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889-896.
6. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994, 20:15-20.
7. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
8. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
9. Neumann U.P., Berg T., Bahra M., Seehofer D., Langrehr J.M., Neuhaus R., et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004, 41:830-836.
10. Samuel D., Bizollon T., Feray C., Roche B., Ahmed S.N., Lemonnier C., et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003, 124:642-650.
11. Carrion J.A., Navasa M., Garcia-Retortillo M., Garcia-Pagan J.C., Crespo G., Bruguera M., et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007, 132:1746-1756.
12. Firpi R.J., Clark V., Soldevila-Pico C., Morelli G., Cabrera R., Levy C., et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009, 15:1063-1071.
13. Berenguer M., Prieto M., San Juan F., Rayon J.M., Martinez F., Carrasco D., et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002, 36:202-210.
14. Firpi R.J., Abdelmalek M.F., Soldevila-Pico C., Reed A., Hemming A., Howard R., et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002, 8:1000-1006.
15. Bizollon T., Ahmed S.N., Radenne S., Chevallier M., Chevallier P., Parvaz P., et al. Long-term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003, 52:283-287.
16. Abdelmalek M.F., Firpi R.J., Soldevila-Pico C., Reed A.I., Hemming A.W., Liu C., et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004, 10:199-207.
17. Yedibela S., Schuppan D., Muller V., Schellerer V., Tannapfel A., Hohenberger W., et al. Successful treatment of hepatitis C re-infection with interferon-alpha2b and ribavirin after liver transplantation. Liver Int 2005, 25:717-722.
18. Picciotto F.P., Tritto G., Lanza A.G., Addario L., De Luca M., Di Costanzo G.G., et al. Sustained virological response to antiviral therapy reduces mortality in HCV re-infection after liver transplantation. J Hepatol 2007, 46:459-465.
19. Walter T., Scoazec J.Y., Guillaud O., Hervieu V., Chevallier P., Boillot O., et al. Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact. Liver Transpl 2009, 15:54-63.
20. Nair S., Khan S., Loss G., Eason J., Blazek J., Lipscomb J., et al. Treatment of recurrent hepatitis C in liver transplant recipients: is there any histologic benefit?. Liver Transpl 2003, 9:354-359.
21. Berenguer M., Palau A., Fernandez A., Benlloch S., Aguilera V., Prieto M., et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006, 12:1067-1076.
22. Fernandez I., Meneu J.C., Colina F., Garcia I., Munoz R., Castellano G., et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006, 12:1805-1812.
23. Neumann U., Puhl G., Bahra M., Berg T., Langrehr J.M., Neuhaus R., et al. Treatment of patients with recurrent hepatitis C after liver transplantation with PEG-interferon alfa-2B plus ribavirin. Transplantation 2006, 82:43-47.
24. Oton E., Barcena R., Moreno-Planas J.M., Cuervas-Mons V., Moreno-Zamora A., Barrios C., et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006, 6:2348-2355.
25. Wiesner R.H., Sorrell M., Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9:S1-S9.
26. Roche B., Sebagh M., Canfora M.L., Antonini T., Roque-Afonso A.M., Delvart V., et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008, 14:1766-1777.
27. Berenguer M., Aguilera V., Prieto M., Ortiz C., Rodriguez M., Gentili F., et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009, 15:738-746.
28. Selzner N., Renner E.L., Selzner M., Adeyi O., Kashfi A., Therapondos G., et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009, 88:1214-1221.
29. Selzner M., Kashfi A., Selzner N., McCluskey S., Greig P.D., Cattral M.S., et al. Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation. Liver Transpl 2009, 15:1288-1295.
30. Rosen H.R., Gretch D.R., Oehlke M., Flora K.D., Benner K.G., Rabkin J.M., et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998, 65:1178-1182.
31. Pelletier S.J., Iezzoni J.C., Crabtree T.D., Hahn Y.S., Sawyer R.G., Pruett T.L. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necro-inflammatory activity. Liver Transpl 2000, 6:44-53.
32. Testa G., Crippin J.S., Netto G.J., Goldstein R.M., Jennings L.W., Brkic B.S., et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000, 6:553-561.
33. Samonakis D.N., Triantos C.K., Thalheimer U., Quaglia A., Leandro G., Teixeira R., et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005, 11:386-395.
34. Charlton M., Seaberg E., Wiesner R., Everhart J., Zetterman R., Lake J., et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28:823-830.
35. Brillanti S., Vivarelli M., De Ruvo N., Aden A.A., Camaggi V., D'Errico A., et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002, 8:884-888.
36. Vivarelli M., Burra P., La Barba G., Canova D., Senzolo M., Cucchetti A., et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007, 47:793-798.
37. Ishii N., Watashi K., Hishiki T., Goto K., Inoue D., Hijikata M., et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 2006, 80:4510-4520.
38. Hirano K., Ichikawa T., Nakao K., Matsumoto A., Miyaaki H., Shibata H., et al. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl 2008, 14:292-298.
39. Villamil F., Levy G., Grazi G.L., Mies S., Samuel D., Sanjuan F., et al. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Transplant Proc 2006, 38:2964-2967.
40. Walter T., Dumortier J., Guillaud O., Hervieu V., Scoazec J.Y., Boillot O. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center. Liver Transpl 2007, 13:294-301.
41. Firpi R.J., Zhu H., Morelli G., Abdelmalek M.F., Soldevila-Pico C., Machicao V.I., et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006, 12:51-57.
42. Group R-TS Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011, 92:334-340.
43. Cescon M., Grazi G.L., Cucchetti A., Vetrone G., Ravaioli M., Ercolani G., et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009, 15:782-789.
44. Zervos X.A., Weppler D., Fragulidis G.P., Torres M.B., Nery J.R., Khan M.F., et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998, 65:1044-1046.
45. Levy G., Grazi G.L., Sanjuan F., Wu Y., Muhlbacher F., Samuel D., et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006, 12:1464-1472.
46. O'Grady J.G., Hardy P., Burroughs A.K., Elbourne D. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007, 7:137-141.
47. Berenguer M., Aguilera V., San Juan F., Benlloch S., Rubin A., Lopez-Andujar R., et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010, 90:1204-1209.
48. Neef M., Ledermann M., Saegesser H., Schneider V., Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006, 45:786-796.